 "sun pharma")
Sun Pharmaceutical Industries dipped 8% to Rs 589, its lowest level since November 2016 on BSE, after the company’s US subsidiary, Taro reported a weak set of numbers for the quarter ended March 2017 (Q4FY17).
Taro Pharmaceutical Industries reported 25.9% year on year (YoY) fall in net sales for Q4FY17 to $196.4 million, due to continuing increased competition and the challenging pricing environment, the company said in a news release.
Net Income attributable to Taro was $ 83 million compared to $ 115 million, resulting in diluted earnings per share of $2.05 compared to $2.68 for the same
Taro Pharmaceutical Industries reported 25.9% year on year (YoY) fall in net sales for Q4FY17 to $196.4 million, due to continuing increased competition and the challenging pricing environment, the company said in a news release.
Net Income attributable to Taro was $ 83 million compared to $ 115 million, resulting in diluted earnings per share of $2.05 compared to $2.68 for the same
